ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

EQ Equillium Inc

0,815
-0,0819 (-9,13%)
08 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Equillium Inc EQ NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
-0,0819 -9,13% 0,815 01:59:22
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,83 0,8009 0,8555 0,801 0,8969
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
05/6/202414:00BWEquillium Reports Inducement Grant Under Nasdaq Listing Rule..
04/6/202414:00EDGAR2Form 8-K - Current report
04/6/202414:00BWEquillium Announces Positive Topline Data from Phase 2 Study..
29/5/202414:00BWEquillium to Present at the Jefferies Global Healthcare..
23/5/202423:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202423:00EDGAR2Form 8-K - Current report
14/5/202414:00BWEquillium Announces Interim Enrollment Achieved in Phase 3..
09/5/202422:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202422:01BWEquillium Reports First Quarter 2024 Financial Results and..
07/5/202414:00BWEquillium Announces Poster Presentation at the Annual..
03/4/202414:00BWEquillium Reports Inducement Grant Under Nasdaq Listing Rule..
01/4/202414:00BWEquillium Announces Positive Topline Data from the Type B..
25/3/202421:01BWEquillium Reports on Fourth Quarter and Full Year 2023..
22/3/202413:00BWEquillium to Present at the H.C. Wainwright Autoimmune &..
08/3/202423:35EDGAR2Form 3 - Initial statement of beneficial ownership of..
08/3/202422:01EDGAR2Form 8-K - Current report
23/2/202423:12EDGAR2Form 8-K - Current report
23/2/202423:09EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
22/2/202412:08EDGAR2Form 8-K - Current report
04/1/202400:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202400:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202400:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202314:05EDGAR2Form 8-K - Current report
21/12/202314:00BWEquillium Announces Update on Multi-Cytokine Inhibitors..
20/11/202317:23PRNCAEQ Bank Card launches in Québec as Carte Banque EQ
13/11/202315:00BWEquillium Presents Positive Data from Phase 1b EQUALISE..
08/11/202322:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202322:05EDGAR2Form 8-K - Current report
08/11/202322:01BWEquillium Reports Third Quarter 2023 Financial Results and..
06/11/202314:00BWEquillium Announces Data from Phase 1b EQUALISE Study..
19/10/202314:00BWEquillium Announces Abstracts Accepted for Presentation at..
16/10/202314:05EDGAR2Form 8-K - Current report
16/10/202314:00BWEquillium Announces Preclinical Data from New Orally..
05/10/202323:28EDGAR2Form 8-K - Current report
05/10/202323:23EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03/10/202314:00BWEquillium to Host Analyst & Investor Day
02/10/202314:00BWEquillium to Present at the JonesTrading 2023 Healthcare..
20/9/202314:00BWEquillium to Present at the Cantor Fitzgerald Global..
30/8/202314:00BWEquillium to Attend Wells Fargo Healthcare Conference &..
09/8/202322:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202322:06EDGAR2Form 8-K - Current report
09/8/202322:01BWEquillium Reports Second Quarter 2023 Financial Results and..
02/8/202322:00BWEquillium Announces $7.5 Million Share Repurchase Program